{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:17:37Z","timestamp":1791357457601,"version":"4.3.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,7,17]],"date-time":"2010-07-17T00:00:00Z","timestamp":1279324800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s11920-010-0135-5","type":"journal-article","created":{"date-parts":[[2010,7,16]],"date-time":"2010-07-16T06:28:52Z","timestamp":1279261732000},"page":"448-453","source":"Crossref","is-referenced-by-count":87,"title":["Use of Naltrexone to Treat Opioid Addiction in a Country in Which Methadone and Buprenorphine Are Not Available"],"prefix":"10.1007","volume":"12","author":[{"given":"Evgeny","family":"Krupitsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Zvartau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Woody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,7,17]]},"reference":[{"key":"135_CR1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.31887\/DCNS.2007.9.2\/hkleber","volume":"9","author":"H Kleber","year":"2007","unstructured":"\u2022 Kleber H: Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci 2007, 9:455\u2013470. This an excellent review of pharmacologic treatments for opioid dependence.","journal-title":"Dialogues Clin Neurosci"},{"key":"135_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0740-5472(96)00164-X","volume":"14","author":"A Roth","year":"1997","unstructured":"Roth A, Hogan I, Farren C: Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals. J Subst Abuse Treat 1997, 14:19\u201322.","journal-title":"J Subst Abuse Treat"},{"key":"135_CR3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jsat.2006.06.002","volume":"31","author":"C O\u2019Brien","year":"2006","unstructured":"O\u2019Brien C, Cornish JW: Naltrexone for probationers and parolees. J Subst Abuse Treat 2006, 31:107\u2013111.","journal-title":"J Subst Abuse Treat"},{"key":"135_CR4","first-page":"39","volume":"45","author":"AM Washton","year":"1984","unstructured":"Washton AM, Pottash AC, Gold MS: Naltrexone in addicted business executives and physicians. J Clin Psychiatry 1984, 45:39\u201341.","journal-title":"J Clin Psychiatry"},{"key":"135_CR5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0376-8716(98)00152-5","volume":"54","author":"KL Preston","year":"1999","unstructured":"Preston KL, Silverman K, Umbricht A, et al.: Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend 1999, 54:127\u2013135.","journal-title":"Drug Alcohol Depend"},{"key":"135_CR6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/archpsyc.58.8.755","volume":"58","author":"KM Carroll","year":"2001","unstructured":"Carroll KM, Ball SA, Nich C, et al.: Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry 2001, 58:755\u2013761.","journal-title":"Arch Gen Psychiatry"},{"key":"135_CR7","first-page":"37","volume-title":"Potentiating the efficacy of medications: Integrating psychosocial therapies with pharmacotherapies in the treatment of drug dependence","author":"B Rounsaville","year":"1995","unstructured":"Rounsaville B: Can psychotherapy rescue naltrexone treatment of opioid addiction? In Potentiating the Efficacy of Medications: Integrating Psychosocial Therapies With Pharmacotherapies in the Treatment of Drug Dependence. Edited by Onken L, Blaine J. Rockville, MD: National Institute on Drug Abuse; 1995:37\u201352. [NIDA Research Monograph series no. 105, NIH publication no. 95-3899.]"},{"key":"135_CR8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0740-5472(02)00301-X","volume":"23","author":"JL Rothenberg","year":"2002","unstructured":"Rothenberg JL, Sullivan MA, Church SH, et al.: Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Abuse Treat 2002, 23:351\u2013360.","journal-title":"J Subst Abuse Treat"},{"key":"135_CR9","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/00952990600918973","volume":"32","author":"EV Nunes","year":"2006","unstructured":"Nunes EV, Rothenberg JL, Sullivan MA, et al.: Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse 2006, 32:503\u2013517.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"135_CR10","volume-title":"Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence","author":"World Health Organization","year":"2009","unstructured":"\u2022\u2022 World Health Organization: Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva, Switzerland: World Health Organization; 2009. The guidelines review the use of medications such as methadone, buprenorphine, naltrexone, and others in combination with psychosocial support in the treatment of individuals dependent on heroin or other opioids. Based on the systematic review of the literature, the guidelines contain specific recommendations on the range of issues faced in organizing treatment systems, managing treatment programs, and treating those who are dependent on opioids."},{"key":"135_CR11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jsat.2004.02.002","volume":"26","author":"EM Krupitsky","year":"2004","unstructured":"Krupitsky EM, Zvartau EE, Masalov DV, et al.: Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat 2004, 26:285\u2013294.","journal-title":"J Subst Abuse Treat"},{"key":"135_CR12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00132576-200205000-00006","volume":"1","author":"EM Krupitsky","year":"2002","unstructured":"Krupitsky EM, Burakov AM, Didenko TY, et al.: Effects of citalopram treatment of protracted withdrawal (syndrome of anhedonia) in patients with heroin addiction. Addict Disord Their Treat 2002, 1:29\u201333.","journal-title":"Addict Disord Their Treat"},{"key":"135_CR13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jsat.2006.05.005","volume":"31","author":"EM Krupitsky","year":"2006","unstructured":"Krupitsky EM, Zvartau EE, Masalov DV, et al.: Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat 2006, 31:319\u2013328.","journal-title":"J Subst Abuse Treat"},{"key":"135_CR14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00213-006-0640-8","volume":"190","author":"R Sinha","year":"2007","unstructured":"Sinha R, Kimmerling A, Doebrick C, Kosten TR: Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Psychopharmacology 2007, 190:569\u2013574.","journal-title":"Psychopharmacology"},{"key":"135_CR15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0924-977X(09)70234-2","volume":"19","author":"E Krupitsky","year":"2009","unstructured":"Krupitsky E, Zvartau E, Woody G: Long acting naltrexone implants for heroin dependence. Eur Neuropsychopharmacol 2009, 19:192.","journal-title":"Eur Neuropsychopharmacol"},{"key":"135_CR16","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/j.1360-0443.2007.01817.x","volume":"102","author":"EM Kruptisky","year":"2007","unstructured":"\u2022 Kruptisky EM, Burakov AM, Tsoy MV, et al.: Overcoming opioid blockade from depot naltrexone (Prodetoxon). Addiction 2007, 102:1164\u20131165. This case describes a situation in which an opioid-dependent patient overcame naltrexone implant blockade.","journal-title":"Addiction"},{"key":"135_CR17","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archgenpsychiatry.2009.130","volume":"66","author":"GK Hulse","year":"2009","unstructured":"\u2022 Hulse GK, Morris N, Arnold-Reed D, et al.: Improving clinical outcomes in treating heroin dependence. Arch Gen Psychiatry 2009, 66:1108\u20131115. This first double-blind, placebo-controlled, randomized clinical trial showed the effectiveness of the single-dose Australian naltrexone implant in comparison with oral naltrexone.","journal-title":"Arch Gen Psychiatry"},{"key":"135_CR18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1192\/bjp.bp.108.055319","volume":"194","author":"N Kun\u00f8e","year":"2009","unstructured":"\u2022 Kun\u00f8e N, Lobmaier P, Vederhus JK, et al.: Naltrexone implants after in-patient treatment for opioid dependence: randomized controlled trial. Br J Psychiatry 2009, 194:541\u2013546. This Norwegian study compared the Australian implantable naltrexone with usual-treatment aftercare.","journal-title":"Br J Psychiatry"},{"key":"135_CR19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/YCO.0b013e3283386578","volume":"23","author":"EM Krupitsky","year":"2010","unstructured":"\u2022\u2022 Krupitsky EM, Blokhina EA: Long acting sustained release formulations of naltrexone for heroin dependence: a review. Curr Opin Psychiatry 2010, 23:210\u2013214. This is a review of the most recent data on the variety of long-acting, sustained-release formulations of naltrexone (implantable and injectable) and their use for opiate dependence, including their efficacy and safety.","journal-title":"Curr Opin Psychiatry"},{"key":"135_CR20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2217\/14796708.1.4.389","volume":"1","author":"RG Volpicelli","year":"2006","unstructured":"Volpicelli RG, Fenton M: Sustained-release naltrexone formulations for the treatment of alcohol and opioid dependence. Future Neurol 2006, 1:389\u2013398.","journal-title":"Future Neurol"},{"key":"135_CR21","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1530-0277.2006.00052.x","volume":"30","author":"JL Dunbar","year":"2006","unstructured":"Dunbar JL, Turncliff RZ, Dong Q, et al.: Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res 2006, 30:480\u2013490.","journal-title":"Alcohol Clin Exp Res"},{"key":"135_CR22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","volume":"63","author":"SD Comer","year":"2006","unstructured":"Comer SD, Sullivan MA, Yu E, et al.: Injectable, sustained-release naltrexone for the treatment of opioid dependence. Arch Gen Psychiatry 2006, 63:210\u2013218.","journal-title":"Arch Gen Psychiatry"},{"key":"135_CR23","unstructured":"Alkermes announces positive results from phase 3 clinical study of naltrexone for extended-release injectable suspension for the treatment of opioid dependence. Cambridge, MA: Alkermes; November 16, 2009. Available at http:\/\/investor.alkermes.com\/phoenix.zhtml?c\u2009=\u200992211&p\u2009=\u2009irol-newsArticle&ID\u2009=\u20091355632&highlight ."},{"key":"135_CR24","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/j.1360-0443.2008.02252.x","volume":"103","author":"M Fishman","year":"2008","unstructured":"\u2022 Fishman M: Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Addiction 2008, 103:1399\u20131401. This clinical case demonstrated that it is possible to overcome opioid blockade with Vivitrol and precipitate withdrawal in some circumstances.","journal-title":"Addiction"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-010-0135-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-010-0135-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-010-0135-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T14:50:28Z","timestamp":1635691828000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-010-0135-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,17]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["135"],"URL":"https:\/\/doi.org\/10.1007\/s11920-010-0135-5","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,17]]}}}